Turning Data and AI Into Better Business Outcomes

Artificial intelligence is reshaping how biopharmaceutical companies discover, develop, commercialize, and support medicines. But realizing its potential requires far more than adopting the latest tools. Srivatsan Nagaraja speaks with Matt Lasmanis, chief digital officer at Jazz Pharmaceuticals, about building a digital, data, and AI strategy grounded in corporate ambition and measurable outcomes. Lasmanis offers a practical framework that begins with strategy, identifies the business outcomes that matter most, and establishes the metrics needed to demonstrate progress. He also discusses how companies can align people, technology, and partners to build enterprise capabilities that advance precision, efficiency, and innovation.